The President’s victory lap on the success of price controls is premature
In a commentary published in the Sarasota Herald-Tribune, NPC's John M. O’Brien discusses the potential effects of new price controls and what the future holds for Medicare.
President Biden and his team have been traveling around the country to tout their policy accomplishments in the past month, including the drug pricing provisions of the Inflation Reduction Act.
In a commentary for the Sarasota Herald-Tribune, NPC President and CEO John M. O’Brien, PharmD, MPH, discusses why it’s premature to declare the new price controls in Medicare a success, breaking down the provisions of the bill and the potential pitfalls.
When my neighbors ask me if this law will help them, the best I can say is this: “It depends.” ...On its face, allowing Medicare to use its purchasing power to “negotiate” lower drug prices sounds like it would obviously benefit seniors. However, this provision is likely to contain several unintended consequences for seniors who rely on prescription drugs.
Read the full commentary in the Sarasota Herald-Tribune.
